Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study

Diabetes Research and Clinical Practice

Volumn 86, Issue 3, 2009, Pages 247-253

  Khalangot, Mykola ^a   Tronko, Mykola ^a   Kravchenko, Victor ^a   Kovtun, Vladimir ^a  

^a V P Komisarenko Institute of Endocrinology and Metabolism of the Ukraine Academy of Medical Sciences   (Ukraine)

Author keywords

Cardiovascular disease; Glibenclamide; Gliclazide; Glimepiride; Mortality; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRESCRIPTION; RISK REDUCTION; TIME OF DEATH; UKRAINE;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; GLICLAZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SULFONYLUREA COMPOUNDS; UKRAINE;

EID: 70350622310     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.09.008     Document Type: Article

References (25)

1. Gribble F.M., and Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J. Diabetes Complications 17 Suppl. 2 (2003) 11-15
2. Wu G.T., Wang L., Li J., and Zhu W.Z. Effects of glibenclamide, glimepiride, and gliclazide on ischemic preconditioning in rat heart. Chin. Med. Sci. J. 22 3 (2007) 162-168
3. Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur. Heart J. 20 March (6) (1999) 439-446
4. Johnsen S.P., Monster T.B.M., Olsen M.L., Thisted H., McLaughlin J.K., Sorensen H.T., et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am. J. Ther. 13 2 (2006) 134-140
5. Monami M., Balzi D., Lamanna C., Barchielli A., Masotti G., Buiatti E., et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab. Res. Rev. 23 6 (2007) 479-484
6. World Health Organization Model List of Essential Medicines (2007). http://www.who.int/medicines/publications/EML15.pdf, retrieved 6 June 2008.
7. Gangji A.S., Cukierman T., Gerstein H.C., Goldsmith C.H., and Clase C.M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30 2 (2007) 389-394
8. Lipscombe L.L., and Hux J.E. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet 369 9563 (2007) 750-756
9. Khalangot M., and Tronko M. Primary care diabetes in Ukraine. Primary Care Diabetes 1 (2007) 203-205
10. Tron'ko N.D., Khalangot N.D., Kravchenko V.I., Kul'chinskaia Ia B., Gur'ianov V.G., and Mis'ko L.A. Incidence of proliferative retinopathy and sex-related differences in death rate among patients with diabetes mellitus and sight impairment treated with insulin (according to the data from national diabetic registry). Lik Sprava 6 (2004) 29-32
11. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 34 August (8) (2004) 535-542
12. Henquin J.C., Garrino M.G., and Nenquin M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms. Eur. J. Pharmacol. 141 September (2) (1987) 243-251
13. Gram J., and Jespersen J. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Am. J. Med. 90 (1991) 62S-66S
14. http://www.who.int/whosis/database/life_tables/life_tables_process.cfm?path=whosis,life_tables&language=english, retrieved 16.06.08.
15. Franco O.H., Steyerberg E.W., Hu F.B., Mackenbach J., and Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 167 11 (2007) 1145-1151
16. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352 (1998) 837-853.
17. Draeger K.E., Wernicke-Panten K., Lomp H.J., Schuler E., and Rosskamp R. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide. Horm. Metab. Res. 28 9 (1996) 419-425
18. Marbury T., Huang W.C., Strange P., and Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43 3 (1999) 155-166
19. Khalangot M., Kravchenko V., Tronko M., and Vaiserman A. Assessment of current insulin usage in type 2 diabetics according to diabetes type distribution among insulin-treated patients in Ukraine. Diabetol. Croatica 36 (2007) 15-21
20. Raccah D. Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49: 930-936. Diabetologia 50 5 (2007) 1109-1110
21. Doro P., Benko R., Kosik E., Matuz M., Toth K., and Soos G. Utilization of oral antihyperglycaemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur. J. Clin. Pharmacol. 61 12 (2005) 893-897
22. Lub R., Denig P., van den Berg P.B., Hoogenberg K., and de Jong-van den Berg L.T. The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus. Br. J. Clin. Pharmacol. 62 6 (2006) 660-665
23. World Health Statistics (2007). http://www.who.int/healthinfo/statistics/en/, retrieved 16.06.08.
24. Khalangot M. Current practice of insulin and oral hypoglycaemic agents treatment of diabetes mellitus type 2 patients according to diabetes mellitus register data analysis in the city of Donetsk, Ukraine. Primary Care Diabetes 1 December (4) (2007) 224
25. M.D. Khalangot, Epidemiologic characteristics of diabetes mellitus type 1 and 2 according to data from national population-based patient register, Manuscript, Thesis for the Degree of Doctor of Medical Sciences, V.P. Komisarenko Institute of Endocrinology and Metabolism AMS of Ukraine, Kiev, 2009.